IL22 and inflammatory bowel disease: Eosinophils [36] and CD4+ T cells have also been shown to express IL-22BP in IBD patients, and have been associated as a pathogenic source of the endogenous inhibitor, in that the protective effects of IL-22 are blocked [10].